Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.39 |
| ▸ | MET | P08581 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MAP4K3 | Q8IVH8 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964765 | 0.85 | MAPK1 (0.65) | MAPK1METJAK2JAK1JAK3 | |
| SCHEMBL31079103 | 0.81 | PARP10 (0.55) | MAPK1PARP10PARP11MAPKAPK2MAPK9 | |
| SCHEMBL29964696 | 0.81 | MAPK1 (0.58) | MAPK1PARP10PARP11MAPKAPK2MAPK9 | |
| SCHEMBL29964732 | 0.79 | MAPK1 (0.52) | MAPK1PARP10PARP11MAPKAPK2MAPK9 | |
| SCHEMBL29964239 | 0.79 | MAPK1 (0.52) | MAPK1PARP10PARP11MAPKAPK2MAPK9 | |
| SCHEMBL29964240 | 0.79 | MAPK1 (0.48) | MAPK1PARP10PARP11MAPKAPK2MAPK9 | |
| SCHEMBL29964252 | 0.78 | ACVRL1 (0.42) | MET | |
| SCHEMBL31079059 | 0.77 | MAPK1 (0.49) | MAPK1PARP10PARP11MAPKAPK2JAK2 | |
| SCHEMBL29965006 | 0.77 | MAPK1 (0.49) | MAPK1PARP10PARP11MAPKAPK2MAPK9 | |
| SCHEMBL31079357 | 0.76 | MAPK1 (0.47) | MAPK1PARP10PARP11MAPKAPK2MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | MAPK1 141/4885ALK 1520/4885EML4 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.